117 related articles for article (PubMed ID: 18082705)
1. Classification of neuroblastomas based on an analysis of the expression of genes related to prognosis.
Tajiri T; Higashi M; Souzaki R; Tatsuta K; Kinoshita Y; Taguchi T
J Pediatr Surg; 2007 Dec; 42(12):2046-9. PubMed ID: 18082705
[TBL] [Abstract][Full Text] [Related]
2. Biological diagnosis for neuroblastoma using the combination of highly sensitive analysis of prognostic factors.
Tajiri T; Tanaka S; Higashi M; Kinoshita Y; Takahashi Y; Tatsuta K; Suita S
J Pediatr Surg; 2006 Mar; 41(3):560-6. PubMed ID: 16516635
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma.
de Souza DR; Sanabani SS; de Souza AC; Filho Odone V; Epelman S; Bendit I
Pediatr Blood Cancer; 2011 May; 56(5):749-56. PubMed ID: 21154590
[TBL] [Abstract][Full Text] [Related]
4. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.
Tajiri T; Liu X; Thompson PM; Tanaka S; Suita S; Zhao H; Maris JM; Prendergast GC; Hogarty MD
Clin Cancer Res; 2003 Aug; 9(9):3345-55. PubMed ID: 12960121
[TBL] [Abstract][Full Text] [Related]
5. Shc family expression in neuroblastoma: high expression of shcC is associated with a poor prognosis in advanced neuroblastoma.
Terui E; Matsunaga T; Yoshida H; Kouchi K; Kuroda H; Hishiki T; Saito T; Yamada S; Shirasawa H; Ohnuma N
Clin Cancer Res; 2005 May; 11(9):3280-7. PubMed ID: 15867224
[TBL] [Abstract][Full Text] [Related]
6. Expression of inhibitor-of-apoptosis protein (IAP) livin by neuroblastoma cells: correlation with prognostic factors and outcome.
Kim DK; Alvarado CS; Abramowsky CR; Gu L; Zhou M; Soe MM; Sullivan K; George B; Schemankewitz E; Findley HW
Pediatr Dev Pathol; 2005; 8(6):621-9. PubMed ID: 16328668
[TBL] [Abstract][Full Text] [Related]
7. Reevaluation of trkA expression as a biological marker of neuroblastoma by high-sensitivity expression analysis--a study of 106 primary neuroblastomas treated in a single institute.
Hishiki T; Saito T; Terui K; Sato Y; Takenouchi A; Yahata E; Ono S; Nakagawara A; Kamijo T; Nakamura Y; Matsunaga T; Yoshida H
J Pediatr Surg; 2010 Dec; 45(12):2293-8. PubMed ID: 21129533
[TBL] [Abstract][Full Text] [Related]
8. Regulation of MYCN expression in human neuroblastoma cells.
Jacobs JF; van Bokhoven H; van Leeuwen FN; Hulsbergen-van de Kaa CA; de Vries IJ; Adema GJ; Hoogerbrugge PM; de Brouwer AP
BMC Cancer; 2009 Jul; 9():239. PubMed ID: 19615087
[TBL] [Abstract][Full Text] [Related]
9. Decreased expression of the candidate tumor suppressor gene ING1 is associated with poor prognosis in advanced neuroblastomas.
Takahashi M; Ozaki T; Todo S; Nakagawara A
Oncol Rep; 2004 Oct; 12(4):811-6. PubMed ID: 15375504
[TBL] [Abstract][Full Text] [Related]
10. Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction.
Gotoh T; Hosoi H; Iehara T; Kuwahara Y; Osone S; Tsuchiya K; Ohira M; Nakagawara A; Kuroda H; Sugimoto T
J Clin Oncol; 2005 Aug; 23(22):5205-10. PubMed ID: 16051962
[TBL] [Abstract][Full Text] [Related]
11. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
Shimada H; Nakagawa A; Peters J; Wang H; Wakamatsu PK; Lukens JN; Matthay KK; Siegel SE; Seeger RC
Cancer; 2004 Oct; 101(8):1873-81. PubMed ID: 15386308
[TBL] [Abstract][Full Text] [Related]
12. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.
Warnat P; Oberthuer A; Fischer M; Westermann F; Eils R; Brors B
BMC Cancer; 2007 May; 7():89. PubMed ID: 17531100
[TBL] [Abstract][Full Text] [Related]
13. Repp86 expression and outcome in patients with neuroblastoma.
Krams M; Heidebrecht HJ; Hero B; Berthold F; Harms D; Parwaresch R; Rudolph P
J Clin Oncol; 2003 May; 21(9):1810-8. PubMed ID: 12721258
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of NTRK family gene expression in neuroblastomas.
Light JE; Koyama H; Minturn JE; Ho R; Simpson AM; Iyer R; Mangino JL; Kolla V; London WB; Brodeur GM
Pediatr Blood Cancer; 2012 Aug; 59(2):226-32. PubMed ID: 21990266
[TBL] [Abstract][Full Text] [Related]
15. Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling.
Schramm A; Schulte JH; Klein-Hitpass L; Havers W; Sieverts H; Berwanger B; Christiansen H; Warnat P; Brors B; Eils J; Eils R; Eggert A
Oncogene; 2005 Nov; 24(53):7902-12. PubMed ID: 16103881
[TBL] [Abstract][Full Text] [Related]
16. The studies on the correlation for gene expression of tyrosine-kinase receptors and vascular endothelial growth factor in human neuroblastomas.
Zhang J; Zheng Y; Wang Y; Tong H
J Pediatr Hematol Oncol; 2010 Apr; 32(3):180-4. PubMed ID: 20186105
[TBL] [Abstract][Full Text] [Related]
17. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
[TBL] [Abstract][Full Text] [Related]
18. Full-length telomerase reverse transcriptase messenger RNA is an independent prognostic factor in neuroblastoma.
Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
Am J Pathol; 2003 Mar; 162(3):1019-26. PubMed ID: 12598334
[TBL] [Abstract][Full Text] [Related]
19. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas.
Eggert A; Ikegaki N; Kwiatkowski J; Zhao H; Brodeur GM; Himelstein BP
Clin Cancer Res; 2000 May; 6(5):1900-8. PubMed ID: 10815914
[TBL] [Abstract][Full Text] [Related]
20. Insights into infant neuroblastomas based on an analysis of neuroblastomas detected by mass screening at 6 months of age in Japan.
Suita S; Tajiri T; Higashi M; Tanaka S; Kinoshita Y; Takahashi Y; Tatsuta K
Eur J Pediatr Surg; 2007 Feb; 17(1):23-8. PubMed ID: 17407017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
